Senti Biosciences Holdings, Inc. SNTI

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001854270

None

No letter

5 of 14 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $51.2M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	short runway, thin data, degenerate in... not computable: dilution, distress, fortress balance sheet
Inputs computable	5 of 14
Graded from	filings received through Apr 29, 2026 184 days before the rescan; latest periodic filing 10-Q received Aug 14, 2026
Last close	$0.22 2026-10-29; market equity $7.0M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 27, 2026

Unless the context otherwise requires, for purposes of this section, the terms "we," "us," "our," "our Company," "the Company" or "Senti" refer to Senti Biosciences, Inc. and its subsidiaries. We are a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with our gene circuit platform technologies for patients living with incurable diseases. Our mission is to create a new generation of smarter medicines that outsmart complex diseases using novel and unprecedented approaches. To accomplish this mission, we have built a synthetic biology platform that we believe may enable us to program next-generation cell and gene therapies with gene circuits.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 17.7						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						

Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						
Accruals ratio	(24.1%)	(6.6%)		17.7	805	2025-12-31
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency, sleeve percentile 78.9						
Twelve-month failure probability	not computable	0.07%				
latest liabilities, cash plus short-term investments, book equity, and shares are required						
Altman Z double-prime	(30.52)	(0.33)		80.8	751	2025-12-31
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(4.51x)				
one or more required annual facts are missing						
Current ratio	1.67x	2.94x		77.0	832	2025-12-31
Growth and financing, sleeve percentile 96.4						
Revenue growth, three-year compound	(81.2%)	10.1%		98.8	413	2025-12-31
Free cash flow growth, three-year compound	not computable	10.9%				
current FCF must be positive and base FCF must exceed $100,000						
Reinvestment rate	not computable	37.1%				
one or more required annual facts are missing						
Asset growth, three years	(34.3%)	2.1%		94.0	697	2025-12-31
Net share issuance, one year	not computable	2.5%				
prior share count is 34 days earlier						

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Short runway	cash runway is 2.0 months
Thin data	5 of 14 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the $100,000 validity floor

What the price implies

at the 2026-10-29 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(73.2%)	7.7%	5
Distance from 52-week high	(90.9%)	(26.6%)	4
EBIT to enterprise value	not computable	(1.4%)	
Free cash flow yield	(645.7%)	(0.9%)	2
Book value to price	(0.50)	0.27	3
Sales to price	0.00	0.30	4
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	(1.53)	(0.14)	5

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$6.5M
Operating cash flow, four quarters	-$38.1M
Months of runway	2.0
Days since last periodic filing	77 (10-Q received Aug 14, 2026)
Median daily dollar volume, 63 sessions	$63,839

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$61.4M	2025-12-31	2026-03-27	10-K	26-021580
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$43.4M	2025-12-31	2026-03-27	10-K	26-021580
3	assets	us-gaap:Assets	$51.2M	2025-12-31	2026-03-27	10-K	26-021580
4	assets	us-gaap:Assets	$97.8M	2024-12-31	2026-03-27	10-K	26-021580
5	current assets	us-gaap:AssetsCurrent	$23.3M	2025-12-31	2026-03-27	10-K	26-021580
6	current liabilities	us-gaap:LiabilitiesCurrent	$14.0M	2025-12-31	2026-03-27	10-K	26-021580
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$358.6M	2025-12-31	2026-03-27	10-K	26-021580
8	operating income	us-gaap:OperatingIncomeLoss	-$68.8M	2025-12-31	2026-03-27	10-K	26-021580
9	book equity	us-gaap:StockholdersEquity	$5.6M	2025-12-31	2026-03-27	10-K	26-021580
10	liabilities	us-gaap:Liabilities	$45.6M	2025-12-31	2026-03-27	10-K	26-021580
11	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$22,000	2025-12-31	2026-03-27	10-K	26-021580
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$0	2024-12-31	2026-03-27	10-K	26-021580
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.0M	2023-12-31	2025-03-20	10-K	25-000042
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$3.3M	2022-12-31	2024-03-21	10-K	24-000029
15	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$196,000	2025-12-31	2026-03-27	10-K	26-021580
16	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$41.4M	2024-12-31	2026-03-27	10-K	26-021580
17	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$26,000	2024-12-31	2026-03-27	10-K	26-021580
18	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$52.4M	2023-12-31	2025-03-20	10-K	25-000042
19	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$12.0M	2023-12-31	2025-03-20	10-K	25-000042
20	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$34.9M	2022-12-31	2024-03-21	10-K	24-000029
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$41.4M	2022-12-31	2024-03-21	10-K	24-000029
22	assets	us-gaap:Assets	$119.5M	2023-12-31	2025-03-20	10-K	25-000042
23	assets	us-gaap:Assets	$180.8M	2022-12-31	2024-03-21	10-K	24-000029
24	shares outstanding	dei:EntityCommonStockSharesOutstanding	31,144,754	2026-04-22	2026-04-29	10-K/A	26-028429
25	shares outstanding	dei:EntityCommonStockSharesOutstanding	31,144,497	2026-03-19	2026-03-27	10-K	26-021580

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.